Athena Technology Acquisition Corp II
Change company Symbol lookup
Select an option...
ATEK Athena Technology Acquisition Corp II
SCGEY Shoucheng Holdings Ltd
PMT-B PennyMac Mortgage Investment Trust
PANW Palo Alto Networks Inc
MDT Medtronic PLC
NUV Nuveen Municipal Value Fund
CZOO+ Cazoo Group Equity Warrants Exp 26th Aug 2026 *W EXP 08/26/2026
CUGCY China Oriental Group Co Ltd
S SentinelOne Inc
OHPAU Orion Acquisition Corp
Go

Company profile

Athena Technology Acquisition Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination. The Company has not commenced any operations nor generated any revenue.

Closing Price
$10.03
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
173

10-day average volume:
198,810
173

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

5:45 am ET October 3, 2022 (PR Newswire) Print

Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders:

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.

If you suffered a loss on your investment in Kiromic, contact us about potential recovery by using the link below. There is no cost or obligation to you.

https://www.wongesq.com/pslra-1/kiromic-biopharma-inc-loss-submission-form?prid=32271&wire=4

ABOUT THE ACTION: The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the "Offering Documents") failed to disclose that the Food and Drug Administration ("FDA") had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ("IND") applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

DEADLINE: October 4, 2022

Aggrieved Kiromic investors only have until October 4, 2022 to request that the Court appoint you as lead plaintiff. You are not required to act as a lead plaintiff in order to share in any recovery.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Vincent Wong, Esq.39 East BroadwaySuite 304New York, NY 10002Tel. 212.425.1140E-Mail: vw@wongesq.com

https://c212.net/c/img/favicon.png?sn=NY89899&sd=2022-10-03

View original content:https://www.prnewswire.com/news-releases/class-action-alert-the-law-offices-of-vincent-wong-remind-kiromic-investors-of-a-lead-plaintiff-deadline-of-october-4-2022-301638128.html

SOURCE The Law Offices of Vincent Wong

https://rt.prnewswire.com/rt.gif?NewsItemId=NY89899&Transmission_Id=202210030545PR_NEWS_USPR_____NY89899&DateId=20221003

comtex tracking

COMTEX_415796731/1005/2022-10-03T05:45:10

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.